Alectos Therapeutics Announces Achievement of Preclinical Milestone in Merck Alzheimer’s Collaboration
Vancouver, British Columbia (November 16, 2012) – Alectos Therapeutics Inc. [...]
O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation
Sweet relief: the Parkinson's disease-associated protein α-synuclein is post-translationally modified [...]
O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment
Deposition of β-amyloid (Aβ) as senile plaques and disrupted glucose [...]
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Oligomerization of tau is a key process contributing to the [...]
Insights into O-linked N-acetylglucosamine ((0-9)O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates
Cellular O-linked N-acetylglucosamine (O-GlcNAc) levels are modulated by two enzymes: [...]
Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis
The O-GlcNAc modification is proposed to be a nutrient sensor [...]
Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes
To probe increased O-GlcNAc levels as an independent mechanism governing [...]
Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody
The microtubule-associated protein tau is known to be post-translationally modified [...]
Alectos Therapeutics Announces Collaboration with Merck to Develop Drugs for Alzheimer’s Disease
Collaboration Targets a Potential Non-Amyloid Approach to Treating Alzheimer’s Disease [...]
Visualizing the reaction coordinate of an O-GlcNAc hydrolase
N-Acetylglucosamine beta-O-linked to serine and threonine residues of nucleocytoplasmic proteins [...]